Logo image of MDNA.CA

MEDICENNA THERAPEUTICS CORP (MDNA.CA) Stock Price, Forecast & Analysis

Canada - TSX:MDNA - CA58490H1073 - Common Stock

1.46 CAD
+0.04 (+2.82%)
Last: 11/17/2025, 7:00:00 PM

MDNA.CA Key Statistics, Chart & Performance

Key Statistics
Market Cap121.78M
Revenue(TTM)N/A
Net Income(TTM)-13.10M
Shares83.41M
Float66.04M
52 Week High2.16
52 Week Low0.78
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.16
PEN/A
Fwd PEN/A
Earnings (Next)02-11 2026-02-11
IPO2015-07-13
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


MDNA.CA short term performance overview.The bars show the price performance of MDNA.CA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 20 30 40 50

MDNA.CA long term performance overview.The bars show the price performance of MDNA.CA in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 50 100 150

The current stock price of MDNA.CA is 1.46 CAD. In the past month the price increased by 52.08%. In the past year, price decreased by -7.01%.

MEDICENNA THERAPEUTICS CORP / MDNA Daily stock chart

MDNA.CA Latest News, Press Relases and Analysis

MDNA.CA Competitors/Peers

The largest stocks on the Canadian markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
EPRX.CA EUPRAXIA PHARMACEUTICALS INC N/A 475.13M
EDT.CA SPECTRAL MEDICAL INC N/A 397.36M
HBP.CA HELIX BIOPHARMA CORP N/A 187.13M
COV.CA COVALON TECHNOLOGIES LTD 24.13 52.92M
MBX.CA MICROBIX BIOSYSTEMS INC N/A 34.88M
RVX.CA RESVERLOGIX CORP N/A 28.67M
BCT.CA BRIACELL THERAPEUTICS CORP N/A 21.43M
HEM.CA HEMOSTEMIX INC N/A 16.56M
MPH.CA MEDICURE INC N/A 13.47M
CSCI.CA COSCIENS BIOPHARMA INC N/A 9.59M
QPT.CA QUEST PHARMATECH INC N/A 7.61M
TELO.CA TELO GENOMICS CORP N/A 7.53M

About MDNA.CA

Company Profile

MDNA logo image Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company. The company is headquartered in Toronto, Ontario and currently employs 18 full-time employees. The company went IPO on 2015-07-13. Its long-acting IL-2 Superkine, MDNA11, is a IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Its IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials, including a Phase IIb trial for recurrent glioblastoma (GBM). Its early-stage high-affinity IL-2B biased IL-2/IL-15 Super-antagonists, from its MDNA209 platform, are being evaluated as potential therapies for autoimmune and graft-versus host diseases. Its early-stage BiSKITs (Bifunctional SuperKine ImmunoTherapies) and the T-MASK (Targeted Metalloprotease Activated SuperKine) programs are designed to enhance the ability of Superkines to treat immunologically cold tumors.

Company Info

MEDICENNA THERAPEUTICS CORP

2 Bloor St W., 7Th Floor

TORONTO ONTARIO M4S 3E2 CA

CEO: Gino L. DeMichele

Employees: 18

MDNA Company Website

MDNA Investor Relations

Phone: 14166485555

MEDICENNA THERAPEUTICS CORP / MDNA.CA FAQ

Can you describe the business of MEDICENNA THERAPEUTICS CORP?

Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company. The company is headquartered in Toronto, Ontario and currently employs 18 full-time employees. The company went IPO on 2015-07-13. Its long-acting IL-2 Superkine, MDNA11, is a IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Its IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials, including a Phase IIb trial for recurrent glioblastoma (GBM). Its early-stage high-affinity IL-2B biased IL-2/IL-15 Super-antagonists, from its MDNA209 platform, are being evaluated as potential therapies for autoimmune and graft-versus host diseases. Its early-stage BiSKITs (Bifunctional SuperKine ImmunoTherapies) and the T-MASK (Targeted Metalloprotease Activated SuperKine) programs are designed to enhance the ability of Superkines to treat immunologically cold tumors.


What is the current price of MDNA stock?

The current stock price of MDNA.CA is 1.46 CAD. The price increased by 2.82% in the last trading session.


Does MDNA stock pay dividends?

MDNA.CA does not pay a dividend.


How is the ChartMill rating for MEDICENNA THERAPEUTICS CORP?

MDNA.CA has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 1 out of 10.


What is MEDICENNA THERAPEUTICS CORP worth?

MEDICENNA THERAPEUTICS CORP (MDNA.CA) has a market capitalization of 121.78M CAD. This makes MDNA.CA a Micro Cap stock.


What is the ownership structure of MEDICENNA THERAPEUTICS CORP (MDNA.CA)?

You can find the ownership structure of MEDICENNA THERAPEUTICS CORP (MDNA.CA) on the Ownership tab.


MDNA.CA Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to MDNA.CA. When comparing the yearly performance of all stocks, MDNA.CA turns out to be only a medium performer in the overall market: it outperformed 63.36% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

MDNA.CA Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to MDNA.CA. MDNA.CA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

MDNA.CA Financial Highlights

Over the last trailing twelve months MDNA.CA reported a non-GAAP Earnings per Share(EPS) of -0.16. The EPS increased by 56.76% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -57.51%
ROE -89.45%
Debt/Equity 0.01
Chartmill High Growth Momentum
EPS Q2Q%-20%
Sales Q2Q%N/A
EPS 1Y (TTM)56.76%
Revenue 1Y (TTM)N/A

MDNA.CA Forecast & Estimates

10 analysts have analysed MDNA.CA and the average price target is 3.57 CAD. This implies a price increase of 144.83% is expected in the next year compared to the current price of 1.46.


Analysts
Analysts82
Price Target3.57 (144.52%)
EPS Next Y-73.4%
Revenue Next YearN/A

MDNA.CA Ownership

Ownership
Inst Owners6.32%
Ins Owners14.23%
Short Float %N/A
Short RatioN/A